Aurinia Pharmaceuticals Inc

We see a constructive medium-term backdrop underpinned by a Bullish Pivot Point pattern signaling failed downside control and upward mean reversion. Price is pulling back into the 50-day SMA and converged 9/20 EMAs, offering a disciplined entry near rising support. The long-term trend remains bullish under a rising 200-day SMA. We recommend Buy Now to capitalize on the pullback interaction at key moving averages.

• ↑Total 2025 revenue reached $283.1M, up 20% YoY.
• ↑Q4 Lupkinis sales surged 29% to $74.2M.
• ↓FDA information request fuels regulatory uncertainty.